[2] Originally founded in 1678, Mitsubishi Tanabe considers itself as one of the oldest pharmaceutical companies in the world.

[3][4] In August 2014, the company announced three-year research collaboration agreement with AstraZeneca on diabetic nephropathy, to replace dialysis or kidney transplantation.

[5] An intravenous treatment of Mitsubishi Tanabe is Radicava (edaravone) which has the goal to slow the decline of physical function in patients with amyotrophic lateral sclerosis (ALS) and was approved by the U.S. Food and Drug Administration in 2017.

The U.S. American branch of Mitsubishi Tanabe created a locator for healthcare and infusion centers.

[1] In 1604, Tanabeya Matazaemon is granted a license by Tokugawa Ieyasu for trade in herbal medicines with Luzon and Siam.

In 1981, Mitsubishi Chemical Industries, Ltd. established a business alliance with Tokyo Tanabe Pharmaceuticals Co.